Post-translational modifications linked to preclinical Alzheimer's disease-related pathological and cognitive changes.
Autor: | Abiose O; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA., Rutledge J; The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.; Department of Genetics, Stanford University, Stanford, California, USA., Moran-Losada P; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.; The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA., Belloy ME; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Wilson EN; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA., He Z; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Center for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, California, USA., Trelle AN; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Channappa D; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Romero A; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Park J; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Yutsis MV; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Sha SJ; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA., Andreasson KI; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.; Chan Zuckerberg Biohub, San Francisco, California, USA., Poston KL; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.; The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA., Henderson VW; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, California, USA., Wagner AD; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.; Department of Psychology, Stanford University, Stanford, California, USA., Wyss-Coray T; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA.; The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA., Mormino EC; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.; Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, California, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Mar; Vol. 20 (3), pp. 1851-1867. Date of Electronic Publication: 2023 Dec 25. |
DOI: | 10.1002/alz.13576 |
Abstrakt: | Introduction: In this study, we leverage proteomic techniques to identify communities of proteins underlying Alzheimer's disease (AD) risk among clinically unimpaired (CU) older adults. Methods: We constructed a protein co-expression network using 3869 cerebrospinal fluid (CSF) proteins quantified by SomaLogic, Inc., in a cohort of participants along the AD clinical spectrum. We then replicated this network in an independent cohort of CU older adults and related these modules to clinically-relevant outcomes. Results: We discovered modules enriched for phosphorylation and ubiquitination that were associated with abnormal amyloid status, as well as p-tau Discussion: In leveraging CSF proteomic data from individuals spanning the clinical spectrum of AD, we highlight the importance of post-translational modifications for early cognitive and pathological changes. (© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.) |
Databáze: | MEDLINE |
Externí odkaz: |